Search

Your search keyword '"Rieborn A"' showing total 6 results
Start Over Author "Rieborn A"
6 results on '"Rieborn A"'

1. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

Author

Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B. A., Westerdijk, Kim, Guchelaar, Niels A. D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L. T, Otten, Hans-Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T. A., Gelderblom, Hans, Moes, Dirk Jan A. R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L. W., Mathijssen, Ron H. J., Huitema, Alwin D. R., van Erp, Nielka P., Desar, Ingrid M. E., and Steeghs, Neeltje

Published
2024
Full Text
View/download PDF

3. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes

Author

Giraud, E.L., Westerdijk, K., van der Kleij, M.B.A., Guchelaar, N.A.D., Meertens, M., Bleckman, R.F., Rieborn, A., Mohammadi, M., Roets, E., Mathijssen, R.H.J., Huitema, A.D.R., Koolen, S.L.W., Gelderblom, H., Moes, D.J.A.R., Reyners, A.K.L., Touw, D.J., Keizer-Heldens, P., Oosten, A.W., van der Graaf, W.T.A., Steeghs, N., van Erp, N.P., and Desar, I.M.E.

Published
2024
Full Text
View/download PDF

4. Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study

Author

van Barele, Mark, Rieborn, Amy, Heemskerk-Gerritsen, Bernadette A. M., Obdeijn, Inge-Marie, Koppert, Linetta B., Loo, Claudette E., Tollenaar, Rob A. E. M., Ausems, Margreet G. E. M., van de Beek, Irma, Berger, Lieke P. V., de Boer, Maaike, van Hest, Liselot P., Kets, C. Marleen, Rookus, Matti, Schmidt, Marjanka K., Jager, Agnes, and Hooning, Maartje J.

Published
2022
Full Text
View/download PDF

5. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

Author

Apotheek O&O&O, Cancer, Medisch Oncologische Disciplines, MS Medische Oncologie, Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B.A., Westerdijk, Kim, Guchelaar, Niels A.D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L.T., Otten, Hans Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T.A., Gelderblom, Hans, Moes, Dirk Jan A.R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L.W., Mathijssen, Ron H.J., Huitema, Alwin D.R., van Erp, Nielka P., Desar, Ingrid M.E., Steeghs, Neeltje, the Dutch Pharmacology Oncology Group (DPOG), Apotheek O&O&O, Cancer, Medisch Oncologische Disciplines, MS Medische Oncologie, Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B.A., Westerdijk, Kim, Guchelaar, Niels A.D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L.T., Otten, Hans Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T.A., Gelderblom, Hans, Moes, Dirk Jan A.R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L.W., Mathijssen, Ron H.J., Huitema, Alwin D.R., van Erp, Nielka P., Desar, Ingrid M.E., Steeghs, Neeltje, and the Dutch Pharmacology Oncology Group (DPOG)

Published
2024

6. Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study

Author

Barele, M. van, Rieborn, A., Heemskerk-Gerritsen, B.A.M., Obdeijn, I.M., Koppert, L.B., Loo, C.E., Tollenaar, R.A.E.M., Ausems, M.G.E.M., Beek, I. van de, Berger, L.P.V., Boer, M. de, Hest, L.P. van, Kets, C.M., Rookus, M., Hebon, Schmidt, M.K., Jager, A., Hooning, M.J., Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Medical Oncology, Radiology & Nuclear Medicine, Surgery, Human genetics, Cancer Center Amsterdam, and CCA - Cancer Treatment and quality of life

Subjects
Cancer Research, PREDICTOR, Survival, Breast Neoplasms, Cohort Studies, Breast cancer, SDG 3 - Good Health and Well-being, STAGE, BRCA2 MUTATION CARRIERS, MANAGEMENT, Humans, Breast, BRCA2 Protein, OUTCOMES, BRCA1 Protein, LYMPH-NODE METASTASIS, WOMEN, Tumor size, Prognosis, BRCA1, BRCA2, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Oncology, Mutation, Female, SUBTYPE
Abstract

Purpose Intensive screening in BRCA1/2 mutation carriers aims to improve breast cancer (BC) prognosis. Our aim is to clarify the prognostic impact of tumor size in BRCA mutation carriers with a pT1 BC, which is currently unclear. We are especially interested in differences between pT1a, pT1b, and pT1c regarding the prognosis of node-negative breast cancer, the effect of chemotherapy, and the prevalence of lymph node involvement. Methods For this study, BRCA1/2-associated BC patients were selected from a nationwide cohort. Primary outcomes were 10-year overall survival (OS) per pT1a-b-c group and the effect of chemotherapy on prognosis of node-negative BC, using Kaplan–Meier and Cox models. Finally, we evaluated lymph node involvement per pT1a-b-c group. Results 963 women with pT1 BRCA1/2-associated BC diagnosed between 1990 and 2017 were included, of which 679 had pN0 BC. After a median follow-up of 10.5 years, 10-year OS in patients without chemotherapy was 77.1% in pT1cN0 and lower than for pT1aN0 (91.4%, p = 0.119) and pT1bN0 (90.8%, p = 0.024). OS was better with than without chemotherapy for pT1cN0 (91.6% vs. 77.1%, p = 0.001; hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.21–1.48). Lymph node involvement was 24.9% in pT1c, 18.8% in pT1b, and 8.6% in pT1a. Conclusion Smaller tumor size is associated with better OS and less lymph node involvement in pT1 BRCA1/2-associated BC patients. The results suggest that early detection in BRCA1/2 mutation carriers of pT1a/b BC may reduce mortality and the need for systemic therapy.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results